Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

2.

Sevabertinib Approved for First-Line Mutated NSCLC

3.

After three years, responses to mounetuzumab in follicular lymphoma are still stable.

4.

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs

5.

AI can identify women at risk of breast cancer years in advance: Study


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot